Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, developed by Vladimir Khavinson’s group in St. Petersburg from the amino-acid makeup of a bovine pineal extract. No regulator has approved it as a medicine, and the dose that circulates online, 5 to 10 mg a day for 10 to 20 days, does not match the amounts used in the three small human studies of the peptide itself. Those studies gave 0.01 mg a day by injection, 0.5 mg a day under the tongue, and 5 micrograms per eye by injection beside the eyeball. This guide tables every amount I could trace, says where each came from, and separates the group’s own work from independent replication.
Ask PeptideBlog about any peptide
Quick answer: There is no approved or established epitalon dose. Published human studies used 0.01 mg a day by intramuscular injection for 10 days, 0.5 mg a day sublingually for 20 days, and 5 micrograms per eye daily for 10 days.[1][2] Online sources most often say 5 to 10 mg a day by subcutaneous injection for 10 to 20 days, repeated every 4 to 6 months, and none of them traces that range to a study of epitalon.[2][22][24] A 10 mg injection amount does appear in the group’s studies of epithalamin, a different pineal extract.[1] More background is on the epithalon research entry.
Figures on this page summarize amounts and schedules reported in published research, regulator documents or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported epitalon amount at a glance
The first block is human work on epitalon itself. The second is a human study of epithalamin, which is a different, animal-derived mixture and is shown only because the 10 mg figure traces there. Then come the regulator documents, animal work, and what circulates online, each row tagged by how good its source is.
Swipe the table sideways to see every column.
| Source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Korkushko and colleagues, 2007 | Elderly adults; 15 epitalon, 15 epithalamin, 10 placebo, plus 10 young reference subjects | Intramuscular | 0.01 mg a day | Daily | 10 days (0.1 mg per course) | Published human study (Tier 1, small); the abstract gives no amount, so it is taken from a 2026 review[1][19] |
| Ivko and colleagues, 2021 (a related 2021 report uses the same women) | 75 women aged 40 to 50, mostly night-shift; 40 with low melatonin output randomized 20 and 20 | Sublingual spray | About 0.5 mg a day (3 sprays twice daily, FDA states 1 mL is about 0.5 mg) | Twice daily | 20 days | Published human study (Tier 1, small)[1][2] |
| Khavinson and colleagues, 2002 | 162 patients (324 eyes), ages 18 to 72, retinitis pigmentosa; 46 comparison patients on usual care | Injection beside the eyeball (parabulbar) | 5 micrograms per eye | Once daily | 10 days (100 micrograms for both eyes) | Published human study (Tier 1, small); not placebo controlled[1] |
| Epithalamin study (not epitalon), 2006 | 70 elderly coronary patients; 36 treated, 34 saline | Intramuscular | 10 mg per injection, 5 injections 3 days apart (50 mg per course) | Courses every 6 months | 3 years of treatment, 12 years of follow-up | Published human study of a different substance[1][21] |
| FDA briefing, nominated products | Nominated compounded products | Subcutaneous injection | 10 mg/mL and 3,000 mcg/mL products; no schedule given | Not stated | Not stated | Regulator document[2] |
| HHS 503A enforcement policy, Appendix A and B | Compounded drug for patients | Subcutaneous or intramuscular | No amount set; epitalon acetate, dispensed in “intermittent courses” | Not stated | Not stated | Regulator document[4] |
| Mice | Female SHR mice, 54 per group | Subcutaneous | 1.0 microgram per mouse | Daily for 5 days each month | From age 3 months to natural death | Published animal research (Tier 3)[8] |
| Rats | Male and female rats | Subcutaneous | 0.1 microgram per rat | 5 times a week | From age 4 months to natural death | Published animal research (Tier 3)[10][11] |
| Rhesus monkeys | Young and old females | Intramuscular | 2 micrograms/kg | Daily | 10 days | Published animal research (Tier 3); dose as stated by FDA[2][12] |
| Human fetal fibroblasts | Cell culture | Added to culture | 50 ng/mL | Continuous | 4 days | Laboratory research (Tier 4); concentration as stated by FDA[2][15] |
| Wellness clinic and education sites | No trial population | Subcutaneous, sometimes oral | 5 to 10 mg a day | Once daily | 10 to 20 days, repeated every 4 to 6 months | Community, vendor or clinic reported (Tier 6); no original source[2][22][24] |
| Wiki community table (90 reports) | Unnamed community reports | Subcutaneous | 1 to 5 mg a day (most often 5 mg for 20 days); higher group 5 to 10 mg | Once daily | 10 to 20 days, 2 to 3 times a year | Community, vendor or clinic reported (Tier 6)[23] |
| Wiki community table, other routes | Unnamed community reports | Oral; intranasal | Oral 5 to 10 mg a day; intranasal 1 to 5 mg a day | Once daily | Oral 10 to 30 days; intranasal 10 to 20 days | Community, vendor or clinic reported (Tier 6); niche[23] |
| Physician slide deck | No trial population | Subcutaneous | 5 mg a day from a 10 mg/mL vial (50 mg per course) | Daily | 10 days, repeated every 6 months | Practitioner reported (Tier 5)[25] |
| Commercial health site | No trial population | Sublingual | 50 to 100 mg a day | Not stated | Not stated | Community, vendor or clinic reported (Tier 6); an outlier, no source[27] |
| Health-membership company page | No trial population | Intranasal | 5 to 20 mg a day in divided doses | Divided | 10 to 30 days | Community, vendor or clinic reported (Tier 6); no source[28] |
| Community group post | One person | Route not stated | 2.5 mg a day | Daily | 20 days | Community, vendor or clinic reported (Tier 6); single anecdote[29] |
| Weight-based dosing (mg per kg) in people | Not applicable | Not applicable | No human weight-based regimen identified | Not applicable | Not applicable | Not consistently reported[1][2] |
The 2007 and 2002 amounts come from a 2026 narrative review. The 2007 abstract states no amount and I could not locate the 2002 report’s abstract, so I could not check either against the primary paper.[1][19] The two 2021 night-shift reports appear to describe overlapping women and should not be counted as two studies.[1]
Where these figures come from
Most epitalon dosing pages online repeat one range and credit it to Khavinson. When I looked for the original, the trail went somewhere else.
- Most-reported figure: 5 to 10 mg a day, 10 to 20 days, repeated every 4 to 6 months. It appears on the wiki, the Peptidepedia page, a telehealth page, and in FDA’s own record of wellness sites it reviewed, which says doses “ranging from 5 mg to 10 mg per day” and cycles, with one site suggesting every 4 months.[2][22][24][26] None cites a trial that used it.
- Human evidence for that figure: none for epitalon. The three human studies used amounts roughly 10 to 1,000 times smaller per day, by other routes.[1][2] That is my arithmetic: 5 to 10 mg a day against 0.5 mg and 0.01 mg a day.
- Possible origin: the epithalamin studies gave 10 mg per injection, five injections per course, 50 mg in total.[1][21] A physician slide deck that lists the same epithalamin course also lists an epitalon course of 5 mg a day for 10 days, which is 50 mg in total.[25] The match in course totals is suggestive. No source I found says the epitalon figure was derived from the extract, so treat it as a lead, not a finding.
- Animal evidence: doses in micrograms per animal, listed below, with no scaling to people.[8][10][11]
- Practitioner figures: one physician slide deck with a promotional code; a clinic page that says its regimen is extrapolated from epithalamin work in adults over 60.[25][26]
- Websites repeating each other: the wiki, Peptidepedia and several clinic pages share the 5 to 10 mg, 10 to 20 day pattern with no reference to a dosing study. The Peptidepedia page lists ten references but gives no study for its dosing tiers, and the wiki page lists none.[22][24]
- Weight-based conversions: none in people. I found no mg-per-kg regimen, and a 2026 review notes dose-ranging and pharmacokinetic data do not exist.[1]
One more unit trap. FDA lists the free base at 390.35 g/mol and the acetate salt at 450.40 g/mol.[2] A milligram of acetate powder therefore holds less peptide than a milligram of free base, about 87 percent by my division, and online pages rarely say which form a vial contains. The units guide covers the milligram, microgram and syringe-mark confusion.
Detailed human data
Reading across the three studies of epitalon itself, I found no dose-ranging design, no pharmacokinetic measurement and no systematic safety reporting.[1] FDA likewise found no human pharmacokinetic data.[2]
Swipe the table sideways to see every column.
| Research objective | Amount studied | Frequency | Duration | Route | Study population | Findings and limits |
|---|---|---|---|---|---|---|
| Circadian melatonin, elderly (Korkushko 2007) | 0.01 mg | Daily | 10 days | Intramuscular | 15 epitalon, 15 epithalamin, 10 placebo; 10 young reference subjects | Night melatonin rose mainly in people with reduced baseline pineal function; the abstract reports no side effects[1][19] |
| Melatonin and clock genes, night-shift women (Ivko 2021) | About 0.5 mg | Twice daily | 20 days | Sublingual spray | 75 women; 40 with low output randomized to AEDG or placebo | Urinary 6-sulfatoxymelatonin rose about 1.7-fold; blinding not specified; safety not systematically reported[1] |
| Retinitis pigmentosa (2002) | 5 micrograms per eye | Daily | 10 days | Parabulbar injection | 162 patients, 46 on usual care | Positive effect reported in about 90 percent; randomization and blinding unclear; no independent replication[1] |
What this means in plain English: epitalon changed a melatonin marker in two small studies, and one older eye study reported benefit against a usual-care comparison. The melatonin studies measured hormone levels, not how anyone slept or lived, and the eye study reported benefit without clear randomization or blinding. The 2026 review calls the human evidence limited to small biomarker studies and one older controlled study in retinitis pigmentosa, with no adequately powered randomized trial.[1]
The epithalamin studies, which are not epitalon
The longevity headlines come from epithalamin. In a 6 to 8 year assessment of 266 older adults, epithalamin treatment was linked to 1.6 to 1.8 times lower mortality than controls.[20] In a randomized 12-year study of 70 people with coronary disease, 28 percent fewer treated patients had died, with 36 treated and 34 on saline.[21] The 2026 review stresses that these used a pineal extract, that a later 15-year follow-up of 79 patients probably overlaps the same participants, and that none of it can be assigned to the synthetic peptide.[1] FDA also treats the two as different substances.[2]
Who has repeated this work
Short version: the human findings have not been independently repeated, and the lab findings have been repeated only in cells. A 2025 review of the physico-chemical and pharmacodynamic literature reaches a similar view of how much is known.[30]
Swipe the table sideways to see every column.
| Claim | Original group | Other labs | Status |
|---|---|---|---|
| Telomerase and telomere length in human cells | Khavinson group, 2003 and 2004: fetal fibroblasts gained telomerase activity, longer telomeres and about 10 extra divisions[15][16] | Brunel University, 2025: longer telomeres in four human cell lines; telomerase rose in normal cells; cancer cells lengthened by an alternative pathway. A correction replaced the first three figures[17][18] | Partly replicated in cells |
| Melatonin release | Reported to raise evening melatonin in old monkeys[12] | A Paris-led perifusion study, co-authored by Khavinson and Anisimov, found no effect on melatonin secretion by rat pineal glands at 10 to the minus 4 to minus 6 molar[14] | Conflicting, in vitro |
| Egg cells and embryos | Not the group’s focus | A Chinese mouse-oocyte study (0.1 mM in culture) and a Korean bovine-oocyte study reported protective effects in vitro[31][32] | Replicated in cell culture |
| Human outcomes | Melatonin markers, retinitis pigmentosa[1] | No independent human study identified[1][2] | Not replicated |
Khavinson or Anisimov is an author on the mouse, rat, monkey, ex vivo pineal, fibroblast and elderly-melatonin papers.[8][10][11][12][14][15][16][19] The exceptions I found are the Sibarov neuron study, the Brunel cell study and the two oocyte studies.[13][17][31][32] The correction matters: per the 2026 review, the corrected paper reports telomerase activity rising in normal cells but not in the two breast cancer lines (21NT, BT474), and telomere length rising in all four lines.[1][17][18] The cell-level finding has not been shown to matter for a person.
Animal and cell amounts
These are per-animal amounts from papers and from FDA’s summary. They are not convertible to human amounts, and I have not tried.
Swipe the table sideways to see every column.
| Research objective | Species or model | Amount studied | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|---|
| Lifespan and tumors | Female SHR mice | 1.0 microgram per mouse (about 30 to 40 micrograms/kg) | Daily for 5 days each month | From age 3 months to death | Subcutaneous | Anisimov 2003[8] |
| Lifespan and tumors | Female CBA mice | Not in the abstract | Not in the abstract | From age 6 months to death | Subcutaneous | Anisimov 2001[9] |
| Lifespan under altered light | Female rats | 0.1 microgram | 5 times a week | From age 4 months | Subcutaneous | Vinogradova 2007[10] |
| Lifespan under altered light | Male rats | 0.1 microgram per rat | 5 times a week | From age 4 months to death | Subcutaneous | Vinogradova 2008[11] |
| Melatonin and cortisol | Young and old female rhesus monkeys | 2 micrograms/kg (FDA summary) | Daily | 10 days | Intramuscular | Goncharova 2001[2][12] |
| Neuron firing | Anesthetized male rats | 30 ng per animal | Single dose | Recorded for up to 30 minutes | Intranasal | Sibarov 2007[13] |
| Tissue distribution | Pregnant rabbits | 30 micrograms/kg, labeled peptide (FDA summary) | Single dose | Not stated | Intravenous | FDA, citing a 2005 study[2] |
| Cell senescence markers | Human stem cells | 0.01 microgram/mL (review) | Continuous | 7 days | In culture | Review[1] |
In SHR mice, epitalon did not change average lifespan, body weight or food intake. It raised the lifespan of the longest-lived tenth by 13.3 percent and maximum lifespan by 12.3 percent, and cut leukemia 6-fold while total tumor incidence was unchanged.[8] In rats under a standard day and night cycle, lifespan did not change; under natural or constant light, maximum lifespan rose by 95 and 24 days in females, and in males the mean lifespan was virtually unchanged.[10][11] FDA, describing the intermittent mouse dosing, put total exposure at about 22 weeks.[2]
Practitioner and community protocols
These are the protocols people actually search for. They are not clinical evidence, and I have given each source’s own numbers.
Swipe the table sideways to see every column.
| Protocol | Amount reported | Route | Frequency | Duration and cycle | Source and date | Source type |
|---|---|---|---|---|---|---|
| Standard injection | 5 to 10 mg a day | Subcutaneous | Once daily, evening preferred | 10 to 20 days; repeat every 4 to 6 months or 2 to 3 times a year | Peptide Protocol Wiki, dosing page, Jan 2026; says the Khavinson group used 10 mg intramuscularly[22] | Wiki; no reference list |
| Wiki community: anti-aging | 1 to 5 mg a day; most common 5 mg for 20 days | Subcutaneous | Once daily | 10 to 20 days, 2 to 3 times a year | Same wiki, community page, Feb 2026, based on 90 reports; cites subreddit front pages only[23] | Community |
| Wiki community: higher dose | 5 to 10 mg a day | Subcutaneous | Once daily | 10 to 20 days, 2 to 3 times a year | Same page, higher-dose group[23] | Community |
| Wiki community: other routes | Oral 5 to 10 mg; intranasal 1 to 5 mg | Oral; intranasal | Once daily | Oral 10 to 30 days; intranasal 10 to 20 days | Same page[23] | Community |
| Education site tiers | 5 mg once daily (conservative); 10 mg once daily; 5 mg twice daily | Subcutaneous | Once or twice daily | 20, 10 and 10 days; repeat once or twice a year | Peptidepedia, dosage page, published January 2025, modified May 2026[24] | Education site |
| Physician slide deck | 5 mg a day (50 mg per course) from a 10 mg/mL vial | Subcutaneous | Daily | 10 days; repeat every 6 months | Lee, slide deck hosted by a medical society, undated; carries a discount code and states no side effects “according to Dr Khavinson”[25] | Practitioner |
| Telehealth page | 5 to 10 mg a day; start at 5 mg for 10 days | Subcutaneous or intramuscular | Once daily | 10 to 20 days; cycles every 4 to 6 months | Marketplace page, May 2026; says the regimen is extrapolated from epithalamin studies in adults over 60[26] | Clinic |
| Commercial site, three routes | Subcutaneous 5 to 10 mg for 10 to 20 days; maintenance 10 mg twice yearly; sublingual 50 to 100 mg; nasal no consensus | Subcutaneous; sublingual; nasal | Not stated | See amount column | Commercial site, revised September 2026; says direct human trial evidence for epitalon is unstable after its own audit[27] | Commercial |
| Membership company page | Injection 5 to 10 mg; nasal 5 to 20 mg in divided doses | Injection; nasal | Divided for nasal | 10 to 20 days; nasal 10 to 30 days | Undated company education page[28] | Company education |
| Group post | 2.5 mg a day | Not stated | Daily | 20 days | Community learning group post, undated[29] | Anecdote |
Reconstitution examples are thin. The wiki says 1 mL of solvent in a 10 mg vial gives 10 mg/mL, and the physician deck uses a 10 mg/mL vial and a half-cc draw (5 mg).[22][25] FDA’s two nominated products were 10 mg/mL and 3,000 mcg/mL.[2] I could not open any specific Reddit thread, so no forum claim is quoted here. The wiki’s own list of Reddit sources links only to subreddit home pages.[23]

Courses, timing, routes
- Intermittent courses: every human regimen I found was short, 10 or 20 days, and the animal work used 5 days a month or 5 days a week.[1][8][10] The HHS policy also uses the phrase “intermittent courses.”[4]
- Repeat interval: “every 4 to 6 months” is a web convention. The epithalamin course was every 6 months, which may be its source.[21][22]
- Time of day: evening dosing is advised on the wiki. No study I found compared times of day.[22]
- Routes: the human studies used intramuscular, sublingual and parabulbar routes; subcutaneous, oral and intranasal amounts appear only online or in animal work.[1][22][23]
Combinations
Formally studied: epithalamin plus Thymalin, a thymus extract, over 6 to 8 years in 266 older adults, and a separate group given Thymalin with epithalamin annually for 6 years. These are extracts, not synthetic peptides.[20] Plausible by mechanism: other short peptides from the same group, such as pinealon and thymogen, which belong to the bioregulator family; I found no epitalon combination trial. Community reported: the wiki lists stacks of epitalon with Thymalin, with pinealon, and with humanin plus MOTS-c.[23] Popularity is not safety data.
Side effects, quality and sourcing risks as reported
No human adverse-event data worth the name exist. The 2007 abstract says the preparations had “no side effects,” and the night-shift study did not report safety systematically.[1][19] FDA searched its adverse event system through 8 December 2025 and found no epitalon reports, which reflects limited use or limited reporting, not safety.[2]
FDA’s concerns are about what is missing. It names immunogenicity and clumping of peptide (aggregation), which it says may be higher by subcutaneous injection, and an unresolved cancer question: lengthening telomeres is linked with cancer risk, and the available animal studies were too limited to settle it.[2] The 2025 cell study also found telomere lengthening in cancer cell lines, through an alternative pathway.[17] Reduced tumor counts in some mouse models do not answer a carcinogenicity question.[1]
Quality risk applies to every non-pharmacy product. FDA’s review found mismatches between the certificates of analysis and the identifiers in the nominations, and a pharmacy compounded epitalon from October 2018 to April 2020 according to a Department of Justice press release FDA cites.[2] A certificate of analysis is the seller’s own claim; the COA guide explains what it can show.
Regulatory status
As of 2 November 2026, in the sources I could open: epitalon is not an FDA-approved drug for any use and I found no approved product in the EU or Japan; FDA says it is in neither the European nor Japanese pharmacopeia.[2] FDA granted an orphan designation for retinitis pigmentosa on 2 September 2010 and it was revoked on 6 January 2016.[2]
Compounding timeline. HHS records epitalon in Category 2 (substances FDA flagged for safety risks) from 29 September 2023 until 22 April 2026, when the nominations were withdrawn.[4][6][7] FDA’s category list of 14 May 2026 no longer shows it in any category.[6] In July 2026 FDA staff proposed not adding either epitalon free base or epitalon acetate to the 503A bulks list, noting no human pharmacokinetics, no adverse event reports, identifier and certificate mismatches, and the immunogenicity and cancer concerns above.[2] On 24 July 2026 the advisory committee discussed epitalon for insomnia and, per HHS, voted in favor of inclusion against its drug center’s recommendation.[3][4] Trade outlets print different tallies, FDA had posted no voting results when I checked, so I print none. A committee vote is advice, not a rule.
HHS policy. A Federal Register notice filed 28 October 2026 and scheduled for 30 October calls its policy both a draft and interim, with comments due about two weeks after publication, around 13 November.[5] It describes enforcement discretion for compounding with listed peptides and says it is not binding.[5] Appendix A lists epitalon, and Appendix B limits it to epitalon acetate as “subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses,” under conditions that include a registered source with a certificate of analysis, a patient-specific prescription and a single active ingredient.[4] That is enforcement discretion, not approval, and state pharmacy rules still apply. The full picture across peptides is on the FDA peptide status page, and the HHS policy post covers the October document. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.
Product sold directly rather than compounded under a prescription is a separate matter: it has no approved labeling or dose, and the policy’s conditions would not apply to it.

What is not public
- Any human pharmacokinetics for epitalon by any route. FDA found none for either form.[2]
- A dose-ranging study. The three human regimens differ by about 50-fold per day and by route, and nobody has compared them.[1]
- A randomized, adequately powered trial for any outcome, including sleep.[1][2]
- Evidence that a subcutaneous dose does anything. FDA noted none of the melatonin studies used that route.[2]
- The source of the 5 to 10 mg a day range. I could not find it in a study of epitalon.
- Long-term safety, cancer risk and immunogenicity.[1][2]
- Dose of any specific vial. Only an independent lab test could say, and the form (free base or acetate) changes the arithmetic.[2]
Frequently asked questions
What is the epitalon dosage?
No approved dosage exists. Published human studies of epitalon used 0.01 mg a day intramuscularly for 10 days, about 0.5 mg a day sublingually for 20 days, and 5 micrograms per eye daily for 10 days. The commonly circulated range of 5 to 10 mg a day is not from those studies.[1][2]
How much epitalon is commonly reported online?
Most pages say 5 to 10 mg a day by subcutaneous injection for 10 to 20 days. A wiki community table also lists 1 to 5 mg a day, with 5 mg for 20 days the most common cycle. These are reported figures from sources that cite no dosing study.[22][23][24]
How long is an epitalon cycle and how often is it repeated?
Online sources say 10 to 20 consecutive days, repeated every 4 to 6 months or 2 to 3 times a year. The human studies used 10 or 20 days, with no study testing the repeat interval.[1][22][24]
Did Khavinson use 10 mg of epitalon?
The 10 mg injection amounts I found are from epithalamin studies, five injections per course, which is a pineal extract and not the synthetic peptide. I did not find a Khavinson epitalon study with a 10 mg daily dose.[1][21]
Is epitalon the same as epithalamin?
No. Epithalamin is a pineal-derived polypeptide preparation. Epitalon is the synthetic four-amino-acid peptide Ala-Glu-Asp-Gly, developed from epithalamin’s amino-acid composition. FDA treats them as different substances.[1][2]
Has epitalon been tested in humans?
Yes, in small studies from the originating research network: melatonin markers in older adults and in night-shift women, and one eye study in retinitis pigmentosa. No adequately powered randomized trial exists, and I found no independent human replication.[1]
Does epitalon lengthen telomeres?
In cultured cells, yes in the group’s own work and in a 2025 independent cell study, which was later corrected. In people it has not been shown. FDA considers the cancer implications of telomere lengthening unresolved.[1][2][15][17][18]
Is epitalon legal or FDA approved?
It is not FDA approved. FDA staff proposed not adding it to the 503A bulks list in July 2026, the advisory committee voted in favor, and an HHS draft policy of October 2026 lists epitalon acetate for injectable compounding in intermittent courses under enforcement discretion. That is not approval.[2][4][5]
How do I reconstitute epitalon?
No label or study sets a method. The wiki example is 1 mL of solvent into a 10 mg vial for 10 mg/mL; FDA recorded nominated products at 10 mg/mL and 3,000 mcg/mL. The reconstitution calculator does the arithmetic once the vial strength and form are known.[2][22]
Bottom line
Epitalon is a short peptide with real laboratory activity and a thin, single-network human record. What is genuinely published: three small human studies at 0.01 mg a day by injection, 0.5 mg a day under the tongue and 5 micrograms per eye, all showing biomarker or functional changes without proof of benefit.[1][2] What is merely reported online: 5 to 10 mg a day by subcutaneous injection for 10 to 20 days every 4 to 6 months, with no traceable source and a possible link to the epithalamin course totals.[22][24][25] What stays speculative: lifespan, telomere effects in people, and sleep. Major limits: no pharmacokinetics, no safety trials and no independent human replication. Regulatory status: not approved, a July 2026 advisory vote in favor of the 503A list against FDA staff advice, and an October 2026 HHS draft policy that allows injectable epitalon acetate compounding under enforcement discretion.[2][4][5] Related: the sister page on NAD+ dosage covers another longevity adjunct, and the evidence standards explain the tiers used here.
Keep reading
Sources
- Jain A, Gallacher DM, Issa MA, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci. 2026;27(19):8922. https://doi.org/10.3390/ijms27198922 PMID 42884164. Open access, read in full. Review (secondary); source for several human amounts whose primary papers I could not open
- U.S. Food and Drug Administration. FDA briefing document for epitalon-related bulk drug substances (epitalon free base and epitalon acetate), Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. https://www.fda.gov/media/193345/download Regulator document. Read through a fetch tool that summarizes; numbers here were cross-checked against the 2026 review where both state them.
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, 23 to 24 July 2026 (agenda and materials). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Regulator document. No minutes or voting results posted when checked.
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (PDF), October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Regulator document
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register notice, document 2026-22192, docket HHS-OASH-2026-0496, filed for public inspection 28 October 2026. https://public-inspection.federalregister.gov/2026-22192.pdf Regulator document
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (Categories 1, 2 and 3). Updated 14 May 2026. https://www.fda.gov/media/94155/download Regulator document
- U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act. Content current as of 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act Regulator document
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. https://doi.org/10.1023/a:1025114230714 PMID 14501183. Published animal research (Tier 3). Same research network.
- Anisimov VN, Khavinson VKh, Zavarzina NIu, et al. Effect of pineal peptide on parameters of the biological age and life span in mice (Russian). Ross Fiziol Zh Im I M Sechenova. 2001;87(1):125-136. PMID 11227856. Published animal research (Tier 3). English abstract only.
- Vinogradova IA, Bukalev AV, Zabezhinski MA, et al. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bull Exp Biol Med. 2007;144(6):825-830. https://doi.org/10.1007/s10517-007-0441-z PMID 18856211. Published animal research (Tier 3)
- Vinogradova IA, Bukalev AV, Zabezhinski MA, et al. Geroprotective effect of Ala-Glu-Asp-Gly peptide in male rats exposed to different illumination regimens. Bull Exp Biol Med. 2008;145(4):472-477. https://doi.org/10.1007/s10517-008-0121-7 PMID 19110597. Published animal research (Tier 3)
- Goncharova ND, Khavinson VKh, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bull Exp Biol Med. 2001;131(4):394-396. https://doi.org/10.1023/a:1017928925177 PMID 11550036. Published animal research (Tier 3). Dose and schedule taken from FDA’s summary.
- Sibarov DA, Vol’nova AB, Frolov DS, Nozdrachev AD. Effects of intranasal administration of epitalon on neuron activity in the rat neocortex. Neurosci Behav Physiol. 2007;37(9):889-893. https://doi.org/10.1007/s11055-007-0095-3 PMID 17955380. Published animal research (Tier 3)
- Djeridane Y, Khavinson VKh, Anisimov VN, Touitou Y. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Invest. 2003;26(3):211-215. https://doi.org/10.1007/BF03345159 PMID 12809170. Laboratory research (Tier 4) (ex vivo rat glands)
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. https://doi.org/10.1023/a:1025493705728 PMID 12937682. Laboratory research (Tier 4)
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. https://doi.org/10.1023/b:bebm.0000038164.49947.8c PMID 15455129. Laboratory research (Tier 4)
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. https://doi.org/10.1007/s10522-025-10315-x PMID 40908429. Laboratory research (Tier 4). Independent group (Brunel University London).
- Al-Dulaimi S, et al. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;27(1):1. https://doi.org/10.1007/s10522-025-10326-8 PMID 41240216. Published erratum (per ref 1 it replaced the first three figures)
- Korkushko OV, Lapin BA, Goncharova ND, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people (Russian). Adv Gerontol. 2007;20(1):74-85. PMID 17969590. Published human study (Tier 1, small). English abstract only; amount from ref 1.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID 14523363. Published human study of epithalamin and Thymalin (not epitalon)
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. https://doi.org/10.1007/s10517-006-0365-z PMID 17426848. Published human study of epithalamin (not epitalon); the 10 mg injection amount is from ref 1
- Peptide Protocol Wiki Team. Epitalon: dosing protocols. Page modified 29 January 2026. https://www.peptideprotocolwiki.com/peptides/epitalon/dosing Community, vendor or clinic reported (Tier 6). Labeled “citations verified” but lists none.
- Peptide Protocol Wiki Team. Epitalon: community protocols and reports. Page updated 16 February 2026. https://www.peptideprotocolwiki.com/peptides/epitalon/community Community, vendor or clinic reported (Tier 6). 90 reports; Reddit links go to subreddit front pages.
- Peptidepedia Medical Advisory Board. Epithalon dosage. Published 15 January 2025, modified 6 May 2026. https://peptidepedia.org/longevity/epithalon/dosage Education site (Tier 6); lists ten papers, none a dosing study
- Lee E. Pineal peptides: epitalon (slide deck), undated, Clinical Peptide Society. https://agemed.org/wp-content/uploads/LEE-Pineal-Peptides-Epitalon.pdf Practitioner reported (Tier 5). Carries a promotional discount code.
- Telehealth marketplace page on adult epitalon dosing, published and updated 25 May 2026 (seller; address held by the editor and not linked on purpose). Community, vendor or clinic reported (Tier 6); says the regimen is extrapolated from epithalamin work
- Commercial health-optimization website, epitalon report, updated 8 September 2026 (shop and affiliate links on the page; address held by the editor and not linked on purpose). Community, vendor or clinic reported (Tier 6)
- Health-membership company, epitalon guide, undated (address held by the editor and not linked on purpose). Community, vendor or clinic reported (Tier 6)
- Community learning group post “A 20 day cycle of Epithalon,” posted 18 February, year not shown (address held by the editor). Community, vendor or clinic reported (Tier 6); single anecdote
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691. https://doi.org/10.3390/ijms26062691 PMID 40141333. Review (secondary)
- Yue X, Liu SL, Guo JN, et al. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes. Aging (Albany NY). 2022;14(7):3191-3202. https://doi.org/10.18632/aging.204007 PMID 35413689. Laboratory research (Tier 4) (mouse oocytes, 0.1 mM in culture)
- Ullah S, Haider Z, Perera CD, et al. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sci. 2025;362:123381. https://doi.org/10.1016/j.lfs.2025.123381 PMID 39788414. Laboratory research (Tier 4) (bovine oocytes)
Educational reference only, not medical advice. This page documents amounts in published research, regulator documents and figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.